Bayer claims full rights to Vitrakvi from Lilly’s Loxo

Eli Lilly and Co. (NYSE:LLY) gained two fewer assets from its acquisition of Loxo Oncology Inc. than planned, as Loxo partner Bayer AG (Xetra:BAYN) said Feb. 15 it will exercise a change-of-control option to acquire full rights to Loxo's sole commercial asset, Vitrakvi larotrectinib, plus LOXO-195.

But Lilly walked away with LOXO-292 -- which it has called the primary value driver of the deal -- plus LOXO-305 (see “Loxo’s FOMO”)...